The pharmacokinetics, pharmacodynamics, clinical efficacy, safety and tolerability of linaclotide

Expert Opinion on Drug Metabolism and Toxicology

Volumn 7, Issue 5, 2011, Pages 651-659

  Lee, Noel ^a   Wald, Arnold ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

constipation; guanylate cyclase C; intestinal secretion; irritable bowel syndrome; laxatives; linaclotide

Indexed keywords

ATRIAL NATRIURETIC FACTOR RECEPTOR; LAXATIVE; LINACLOTIDE; LUBIPROSTONE; PLACEBO;

ABDOMINAL PAIN; ARTICLE; BLOATING; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL MOTILITY; HUMAN; INTESTINE SECRETION; IRRITABLE COLON; MEDICAL LITERATURE; MOLECULAR PATHOLOGY; QUALITY OF LIFE;

ADULT; ANIMALS; CHILD; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; CONSTIPATION; DRUG DESIGN; GUANYLATE CYCLASE; HUMANS; IRRITABLE BOWEL SYNDROME; PEPTIDES;

EID: 79955087420     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2011.572875     Document Type: Article

References (19)

1. Stewart WF, Liberman JN, Sandler RS, et al. Epidemiology of constipation (EPOC) study in the United States: relation of clinical subtypes to sociodemographic features. Am J Gastroenterol 1994;7:3530-40
2. Wald A, Scarpignato C, Kamm MA, et al. The burden of constipation on quality of life: results of a multinational survey. Aliment Pharmacol Ther 2007;26:227-36 (Pubitemid 46985504)
3. Eutamene E, Bradesi S, Laruche M, et al. Guanylate cyclase C-mediated antinociceptive effects of linaclitide in rodent models of visceral pain. Neurogastroenterol Motil 2010;22:312-e84
4. Bharucha AE, Waldman SA. Taking a lesson from microbial diarrheagenesis in the management of chronic constipation. Gastroenterology 2010;138:813-25
5. Johanson JF, Morton D, Geenen J, et al. Multicenter, 4 week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol 2008;103:170-7
6. Quigley EM, Vandeplassche L, Kerstens R, et al. Clinical trial: the efficacy, impact of quality of life and safety and tolerability of prucalopride in severe chronic constipation-a 12 week, randomized, double-blind, placebo controlled trial. Aliment Pharmacol Ther 2009;29:315-28
7. Goldberg M, Li YP, Mangel AM, et al. Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation-a 4 week randomized, double blind, placebo controlled, dose-response study. Aliment Pharm Ther 2010;32:1102-12
8. Currie MG, Kurtz CB, Mahajan-Miklos S, et al. Effects of a single dose administration of MD-1100 on safety, tolerability, exposure, and stool consistency in healthy subjects. Am J Gastroenterol 2005;100:S328
9. Forte LJ. Uroguanylin and guanylin peptides: pharmacology and experimental therapeutics. Pharmacol Ther 2004;104:137-62
10. Hamra FK, Eber SL, Chin DT, et al. Regulation of intestinal uroguanylin/guanylin receptor mediated responses by mucosal acidity. Proc Natl Acad Sci USA 1997;94:2705-10 (Pubitemid 27136940)
11. Busby RW, Bryant AP, Bartolini WP, et al. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur J Pharm 2010;649:328-35
12. Lucas KA, Pitari GM, Kazerounian S, et al. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev 2000;52:375-414
13. Kurtz CB, Fitch D, Busby RW, et al. Effects of multidose administration of MD-1100 on safety, tolerability, exposure, and pharmcodynamics in healthy subjects. Gastroenterology 2006;130(Suppl 2):A 26
14. Andresen V, Camilleri M, Busciglio IA, et al. Effect of 5 days of linaclotide on transit and bowel function in females with constipation- predominant irritable bowel syndrome. Gastroenterology 2007;133:761-8 (Pubitemid 47374145)
15. Johnston JM, Kurtz CB, Drossman DA, et al. Pilot study on the effects of linaclotide in patients with chronic constipation. Am J Gastroenterol 2009;104:125-32
16. Lembo AJ, Johnston JM, MacDougall JE, et al. Efficacy of linaclotide for patients with chronic constipation. Gastroenterology 2010;138:886-95
17. Johnston JM, Kurtz CB, MacDougall JE, et al. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome. Gastroenterology 2010;139(6):1877-86
18. Lembo A, Schneier H, Lavins BJ, et al. Efficacy and safety of once daily linaclotide administered orally for 12-weeks in patients with chronic constipation: results from 2 randomized, double-blind, placebo-controlled phase 3 trials (abstract 286). Presented at Digestive Disease Week (DDW) 2010 in New Orleans, LA
19. Bharucha AE, Linden DR. Linaclotide-a secretagogue and antihyperalgesic agent-what next? Neurogastro Motil 2010;22:227-31